MCT’s collaboration with Onxeo on HCC Phase III study in Middle East

Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag

简体中文 ZH-CN English EN